New England Structural Biology Association (NESBA) presents a one day conference on Exploiting Genomic Instability in Cancer: DNA Damage and Immuno Oncology.
Immunotherapies, including checkpoint inhibitors and adoptive transfer therapies, are revolutionizing cancer treatment. Neoantigens arising as a result of high mutational rates seem to drive the efficacy of immunotherapies, enhancing T cell reactivity against tumor cells. This is leading to increasing evidence of a positive correlation between mutational burden and clinical outcome of immunotherapies. During this meeting we will investigate the implications of genomic instability as a driver of the efficacy of immunotherapies, covering important aspects such as the exploration of genomic instability to enhance the clinical activity of immunotherapies.
Thursday, June 30, 2016
8:00 am - 6:00 pm
|8:00-8:50 AM||Registration and light breakfast|
|8:50-9:00 AM||Opening remarks: Vanessa Almendro/Boris Engels|
|Immune system-centric mechanisms in IO: additional
Boris Engels (Novartis Institutes for BioMedical Research)
|9:00-10:00|| Keynote: Glenn Dranoff, (Novartis Institutes for
"Mechanism of protective tumor immunity"
|10:00-10:45|| Matthew Goldstein, (Neon Therapeutics)|
“Neoantigen Vaccine Combinations"
|11:00-11:45|| Shadmehr (Shawn) Demehri, (Massachusetts General Hospital)|
“Immune Regulation of Early Carcinogenesis”
|11:45-12:30|| Mark Cobbold, (Massachusetts General Hospital)|
“Role of phosphopeptides in immune recognition of cancer cells”
| Tumor cell centric mechanisms in IO: mutational load
and DNA damage|
Vanessa Almendro (Vertex Pharmaceuticals)
|1:30-2:15||Ana C Anderson, (Brigham and Women’s Hospital)|
“Distinct biological roles of checkpoint receptors”
|2:15-3:00|| Christina Pfirschke, (Massachusetts General Hospital)|
“Strategies to enhance patient responses to checkpoint inhibitors”
|3:15-4:00|| Kenzie McIsaac, (Novartis Institutes for BioMedical
"DNA-damage, mutation burden and the tumor microenvironment: what can we learn from genomics data?"
|4:00-4:30|| Lori Taylor, (Vertex Pharmaceuticals)|
"The Impact of IO on the Future Oncology Landscape"
|4:30-6:00||Mixer / Networking session|
Maps, Directions & Lodging Information
Our full-day event will take place at Bentley University. Please click here to find directions and detailed information on area lodging.